Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of EGFR Monoclonal Antibody (Cetuximab/Nimotuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With EGFR-amplification Advanced Gastric Cancer

NCT04136600 is registered in ClinicalTrials.gov with Shanghai Changzheng Hospital as lead sponsor.

NCT NCT04136600
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04136600 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of EGFR Monoclonal Antibody (Cetuximab/Nimotuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With EGFR-amplification Advanced Gastric Cancer
Lead sponsor
Shanghai Changzheng Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
July 1, 2019
Completion date
December 31, 2021
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cetuximab, gastric cancer, nimotuzumab